HSBC to Require Vaccine Pass for Hong Kong Employees
(Bloomberg) -- HSBC Holdings Plc will require all employees to have a valid vaccine pass to enter its premises in Hong Kong from March 28, as the Asian financial hub battles its worst outbreak since the pandemic started.
“All HSBC employees, contractors and third parties will need to be vaccinated or have a valid medical exemption to enter any HSBC premises, including all branches,” the bank said in a memo on Wednesday. The new requirement won't apply to customers entering HSBC branches. A spokesman for the lender confirmed the content of the memo.
The Hong Kong Monetary Authority last month urged banks to consider imposing a vaccine mandate at the workplace and required them to inform the regulator whether they will do so. Goldman Sachs Group Inc. earlier introduced rules requiring all staff to get their shots before entering the office from Feb. 24.
After two years of limited outbreaks, Hong Kong is now facing its toughest challenge of the pandemic, with the highly transmissible omicron variant testing its zero-tolerance, high intensity approach to keeping Covid out. New cases have ballooned from a few hundred a day to more than 30,000 a day and the city has one of the world's highest Covid death rates.
Hong Kong is planning a four-day limited lockdown at the start of a compulsory Covid-19 testing blitz for the city's 7.5 million people later this month, local news outlet HK01 reported Wednesday.
HSBC's vaccine pass will be implemented in three phases to allow ample time for staff to be vaccinated, according to the memo. At least one dose of a vaccine or valid medical exemption will be required for entry from March 28, with the number of doses stepping up in April and June, it added.
Clients unable to provide a vaccine pass in the HSBC main building or HSBC Center will be able to meet in designated areas, the memo said.
©2022 Bloomberg L.P.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.